Damora Therapeutics reports stronger DMR-001 potency against CALR mutations in preclinical studies

PUBT · 1d ago
Damora Therapeutics reports stronger DMR-001 potency against CALR mutations in preclinical studies
  • Damora Therapeutics will present new DMR-001 preclinical results at the American Society of Hematology annual meeting on December 12, 2026.
  • DMR-001 showed stronger inhibition of disease-driving cell proliferation than a reference antibody across additional CALR mutations, extending previously presented findings.
  • The investigational therapy is undergoing Phase 1/1b testing in CLARITY-101 for mutant CALR-driven essential thrombocythemia and myelofibrosis.
  • A December 13 trial-in-progress presentation will outline a design intended to accelerate dose selection for planned expansion cohorts.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Damora Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040900PRIMZONEFULLFEED9869778) on November 04, 2026, and is solely responsible for the information contained therein.